The companies plan to study the effects of psychiatric drugs in the brain at the molecular level with the help of biomarkers and Philips' medical imaging technology. As part of the agreement, scientists from Organon will work at the Philips Life Sciences Facilities in Eindhoven to identify, validate, and exploit novel biomarkers.
David Nicholson, executive vice president R&D of Organon, said: “We are convinced that biomarker research will accelerate the R&D process and improve the success rate of developing new molecular and biological therapies. In particular, our drug development programs for treatment of psychiatric and immune disorders are expected to benefit from this collaborative research effort with Philips.”